Idera Pharmaceuticals Inc. [NASDAQ: IDRA] closed the trading session at $5.40 on 01/19/21. The day’s price range saw the stock hit a low of $4.55, while the highest price level was $5.85. The company report on January 11, 2021 that Idera Pharmaceuticals to Present at Upcoming Conferences.
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced that it will provide a company outlook for 2021 at upcoming conferences.
“2021 represents a pivotal inflection point for Idera, one in which we anticipate that data soon to be available from our ILLUMINATE program will show that tilsotolimod, the most advanced TLR9 agonist therapy in development, can offer meaningful alternatives to patients suffering from advanced anti-PD-1 refractory melanoma and, potentially, colorectal cancer,” stated Vincent Milano, Idera’s Chief Executive Officer. “We’re looking forward to sharing topline response data from ILLUMINATE-301 late in this quarter and a data update from ILLUMINATE-206 in the third quarter of the year.”.
The stocks have a year to date performance of 47.14 percent and weekly performance of 27.36 percent. The stock has been moved at 104.55 percent over the last six months. The stock has performed 16.13 percent around the most recent 30 days and changed 138.94 percent over the most recent 3-months.
If compared to the average trading volume of 383.91K shares, IDRA reached to a volume of 1241319 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Idera Pharmaceuticals Inc. [IDRA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IDRA shares is $7.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IDRA stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Idera Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 24, 2018. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on August 15, 2018, representing the official price target for Idera Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on IDRA stock.
The Average True Range (ATR) for Idera Pharmaceuticals Inc. is set at 0.45
IDRA stock trade performance evaluation
Idera Pharmaceuticals Inc. [IDRA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 27.36. With this latest performance, IDRA shares gained by 16.13% in over the last four-week period, additionally plugging by 104.55% over the last 6 months – not to mention a rise of 151.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IDRA stock in for the last two-week period is set at 71.79, with the RSI for the last a single of trading hit 80.27, and the three-weeks RSI is set at 67.43 for Idera Pharmaceuticals Inc. [IDRA]. The present Moving Average for the last 50 days of trading for this stock 4.06, while it was recorded at 4.54 for the last single week of trading, and 2.55 for the last 200 days.
Idera Pharmaceuticals Inc. [IDRA]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Idera Pharmaceuticals Inc. [IDRA] shares currently have an operating margin of -3168.92. Idera Pharmaceuticals Inc.’s Net Margin is presently recorded at -3902.97.
Return on Total Capital for IDRA is now -170.30, given the latest momentum, and Return on Invested Capital for the company is -210.39. Return on Equity for this stock declined to -213.97, with Return on Assets sitting at -93.79.
Reflecting on the efficiency of the workforce at the company, Idera Pharmaceuticals Inc. [IDRA] managed to generate an average of -$1,569,861 per employee.Idera Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.60 and a Current Ratio set at 4.60.
Earnings per share (EPS) analysis for Idera Pharmaceuticals Inc. [IDRA] stock
With the latest financial reports released by the company, Idera Pharmaceuticals Inc. posted -1.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -402.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IDRA.
Idera Pharmaceuticals Inc. [IDRA]: Insider Ownership positions
There are presently around $48 million, or 25.20% of IDRA stock, in the hands of institutional investors. The top three institutional holders of IDRA stocks are: BAKER BROS. ADVISORS LP with ownership of 4,608,786, which is approximately 0% of the company’s market cap and around 1.70% of the total institutional ownership; VANGUARD GROUP INC, holding 967,577 shares of the stock with an approximate value of $5.22 million in IDRA stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $5.18 million in IDRA stock with ownership of nearly -7.008% of the company’s market capitalization.
Positions in Idera Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 15 institutional holders increased their position in Idera Pharmaceuticals Inc. [NASDAQ:IDRA] by around 598,515 shares. Additionally, 20 investors decreased positions by around 614,146 shares, while 13 investors held positions by with 7,615,769 shares. The mentioned changes placed institutional holdings at 8,828,430 shares, according to the latest SEC report filing. IDRA stock had 4 new institutional investments in for a total of 338,144 shares, while 7 institutional investors sold positions of 117,796 shares during the same period.